SOURCE: SpectraScience, Inc.

SpectraScience, Inc.

April 12, 2016 09:15 ET

SpectraScience Announces Training of Physicians in Kuwait City

SAN DIEGO, CA--(Marketwired - April 12, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that training in use of the WavSTAT4 Optical Biopsy System® was completed at Al Sabah Hospital in Kuwait City on April 6th. Eight physicians were trained on the system, including the Chief of the Gastroenterology and Hepatology Department, Dr. Wafaa al Hashash. 

"This is an exciting first step in the commercialization of WavSTAT as a standard diagnostic tool for sale in the Middle East," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. "Our system is fast, easy to use and requires very little training for the clinician since it is an adjunct to the existing colonoscopy procedure. The WavSTAT Optical Biopsy System gives every clinician diagnostic capability equal to that of experts."

About SpectraScience, Inc.:

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.

For more information:

Visit our web site www.spectrascience.com

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information